Orexo
15,1SEK +4,28%Vær den første som følger denne virksomhed
Orexo develops drugs and digital therapies that meet needs, especially in the area of mental health and diseases related to drug and drug abuse. The products are commercialized by Orexo in the USA or through partners all over the world. The main market is the American market for buprenorphine / naloxone products, where Orexo commercializes the main drug Zubsolv®, for the treatment of opioid dependence. The head office, where research and development work is conducted, is located in Uppsala.
Omsætning
624,3 mio.
EBIT %
-29,46 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ORX
Daglig lav / høj pris
14,5 / 15,42
SEK
Markedsværdi
524,13 mio. SEK
Aktieomsætning
81,26 t SEK
Volumen
5,4 t
Seneste videoer
Finanskalender
Årsrapport
08.02.2024
Generalforsamling
26.04.2024
Delårsrapport
08.05.2024
Delårsrapport
17.07.2024
Delårsrapport
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo A/S | 27,8 % | 27,8 % |
Avanza Pension | 7,6 % | 7,6 % |
Premium
Not activated
This content is for our Premium customers only.
ViserAlle indholdstyper